NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
More than 70 % of patients with breast cancer have estrogen-receptor-positive tumors (ER+) and are considered hormone- sensitive. That is why a vast majority of patients with early operable tumors receive adjuvant endocrine therapy. Patients with metastatic ER+ breast cancer also receive hormone t...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , , , , , , |
|---|---|
| Formáid: | Alt |
| Teanga: | Rúisis |
| Foilsithe / Cruthaithe: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2018-07-01
|
| Sraith: | Сибирский онкологический журнал |
| Ábhair: | |
| Rochtain ar líne: | https://www.siboncoj.ru/jour/article/view/758 |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|